Sonoma Pharmaceuticals (SNOA) Common Equity (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Common Equity of $3.1 million for Q1 2026, down 29.83% year-over-year from $4.4 million in Q1 2025, and down 9.82% quarter-over-quarter from $3.4 million in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Common Equity (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Common Equity history runs 16 years deep, the most recent figure standing at $3.1 million for Q1 2026.
- In Q1 2026, Common Equity fell 29.83% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 29.83% YoY), while the FY2026 annual figure was $3.1 million, down 29.83% from the prior year.
- Common Equity for Q1 2026 stood at $3.1 million, down from $3.4 million in the prior quarter.
- The five-year high for Common Equity was $8.7 million in Q1 2022, with the low at $3.1 million in Q1 2026.
- The 5-year median for Common Equity is $5.6 million (2022), against an average of $5.7 million.
- Peak annual rise in Common Equity reached 72.24% in 2022, while the deepest fall reached 50.23% in 2022.
- Sonoma Pharmaceuticals' Common Equity stood at $5.6 million in 2022, then grew by 20.38% to $6.7 million in 2023, then declined by 27.23% to $4.9 million in 2024, then decreased by 29.53% to $3.4 million in 2025, then declined by 9.82% to $3.1 million in 2026.
- Business Quant data shows SNOA's Common Equity at $3.1 million in Q1 2026, $3.4 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 6.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.59 Mn |
| Mar 31, 2026 | 3.10 Mn |
| Dec 31, 2025 | 3.43 Mn |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 4.06 Mn |
| Mar 31, 2025 | 4.41 Mn |
| Dec 31, 2024 | 4.87 Mn |
| Sep 30, 2024 | 5.35 Mn |
| Jun 30, 2024 | 4.98 Mn |
| Mar 31, 2024 | 6.14 Mn |
| Dec 31, 2023 | 6.69 Mn |
| Sep 30, 2023 | 5.68 Mn |
| Jun 30, 2023 | 7.24 Mn |
| Mar 31, 2023 | 7.98 Mn |
| Dec 31, 2022 | 5.56 Mn |
| Sep 30, 2022 | 7.02 Mn |
| Jun 30, 2022 | 7.96 Mn |
| Mar 31, 2022 | 8.70 Mn |
| Dec 31, 2021 | 11.17 Mn |
| Sep 30, 2021 | 11.46 Mn |